Extended, Tapered Vancomycin Regimen Reduces C diff Recurrence

Tapering vancomycin dosing for 2 weeks after a 2-week standard dose treatment of Clostridioides difficile infection (CDI) resulted in a lower rate of recurrent infection, in a recent randomized controlled trial conducted at 12 Canadian Hospitals.¹ Lead author Emily McDonald, MD, MSc, McGill University Health Centre, Centre for Outcomes Research and Evaluation, Montreal, Quebec, Canada, and colleagues explain that even with initially successful treatment, approximately 20 to 25% of patients develop recurrent CDI within 8 weeks.

Although comparative trials have favored fidaxomicin over vancomycin in treating and reducing recurrence of CDI, the investigators note that it is not universally available, or affordable. They sought to determine whether this pulse and taper vancomycin regimen could also lower rates of recurrence relative to standard dosing.

McDonald and colleagues noted that longer pulse and taper regimens have been used in recurrent CDI, and that in-vitro gut models have shown its promise in preventing recurrence.They also found support for this approach in the trials that had ostensibly demonstrated superiority of fidaxomicin to vancomycin in reducing recurrence.Although there had been a substantial difference in relapse rate between the agents within 14 days of stopping vancomycin, they noted that the rates were similar with longer regimens of vancomycin.

"This is relevant as the duration of vancomycin treatment for CDI arose from limited animal and observational data, potentially derived from a single case report of resolution following 10 days of treatment," McDonald and colleagues argue.

"Furthermore, despite the availability of fidaxomicin and newer treatments for CDI during the last 10 to 15 years, a recent international survey found that more than 66% of clinicians still use vancomycin for the initial treatment of CDI," they related.

McDonald and colleagues conducted a parallel-design double blind trial, The Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection (TAPER-V), with 275 patients with first episode or first recurrence of CDI. All patients received the 2-week standard vancomycin regimen (125mg orally four times daily); and were randomized to receive either an additional 2-weeks of placebo (n=136), or a tapered regimen (n=139) consisting of 125mg orally twice daily for 7 days then once daily for 7 days. Factors that would exclude patients from participating included receiving treatment of the current episode with fidaxomicin, metronidazole, fecal microbiota transplant, or immunoglobulin.

The primary outcome measure was recurrence of CDI between days 15 and 56; and secondary outcomes included recurrence rates at day 38, for direct comparison with the parameters of the fidaxomicin trials.

The investigators reported recurrence of CDI at day 56 in 20 of 135 patients (14.8%) in the vancomycin pulse and taper group, and in 23 of 130 (17.7%) of those in the pulse group (aRR 0.84, 95% CrI 0.48-1.45); with a calculated 73.8% probability of superiority. Recurrence at day 38 occurred in 9 of 135 (6.7%) in the pulse and taper group compared with 20 of 130 (15.4%) in the pulse group (aRR 0.43, 0.19-0.89), corresponding to 99% probability of superiority.Adverse effects were reported as "rare" in both groups.

"The vancomycin pulse and taper regimen could be an option for cases where fidaxomicin is not accessible, and/or where delaying recurrence is important—eg, among more frail, older, patients with more comorbidities," McDonald and colleagues suggest.

Reference

1. McDonald EG, Butler-Laporte G, Brophy JM, et al. Initial vancomycin taper for the prevention of recurrent Clostidioides difficile infection. A randomized clinical trial. JAMA Netw Open. 2026 Feb 27;9(2):e2560495. doi10.1001/jamanetworkopen.2025.60495.